gene therapy, FDA and PTC

FDA grants accelerated approval for PTC’s AADC deficiency gene therapy
This therapy is designed to address the needs of children and adults with aromatic L-amino acid decarboxylase (AADC) deficiency. The FDA's accelerated approval is based on the saf
PTC wins FDA approval for first brain-delivered gene therapy Kebilidi
The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy has already been approved to treat AADC deficiency in Europe and the U.K., among other countries,
PTC Therapeutics Gains Buy Rating Following FDA Approval of Groundbreaking Gene Therapy Kebilidi
Sami Corwin has given his Buy rating due to a combination of factors that favor PTC Therapeutics’ market position. The recent FDA approval of Kebilidi, a groundbreaking gene therapy for AADC deficiency, is a significant milestone for the company.
PTC gets FDA okay for first brain-delivered gene therapy
Kebilidi is the first gene therapy approved by the FDA for administration directly into the brain, given via a cannula during a surgical procedure, and replaces the human dopa decarboxylase (DDC) gene that is mutated in the disease, allowing dopamine synthesis to take place.
PTC Therapeutics’ gene therapy, Kebilidi to treat AADC deficiency receives US FDA approval
PTC Therapeutics’ gene therapy, Kebilidi to treat AADC deficiency receives US FDA approval: Warren, New Jersey Friday, November 15, 2024, 10:00 Hrs [IST] PTC Therapeutics, Inc.,
FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency
The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency.
Reuters1d
US FDA approves PTC Therapeutics' gene therapy for ultra-rare disorder
Nov 13 (Reuters) - The U.S. Food and Drug Administration approved PTC Therapeutics' (PTCT.O), opens new tab gene therapy to ...
Hosted on MSN10h
PTC Industries reports over 100% jump in Q2 PAT; shares up 125% in 1 year
PTC Industries is a smallcap company. It is a manufactures of high precision metal castings for a variety of industries. The ...
PTC Therapeutics price target raised to $45 from $43 at Barclays
Barclays raised the firm’s price target on PTC Therapeutics (PTCT) to $45 from $43 and keeps an Equal Weight rating on the shares. After ...
PTC forecasts quarterly revenue below estimates on tight tech spending
Industrial software maker PTC forecast first-quarter revenue below estimates on Wednesday, signaling continued weakness in ...
An Overview of PTC's Earnings
Analysts expect PTC to report an earnings per share (EPS) of $1.45. PTC bulls will hope to hear the company announce they've ...
Mint1d
PTC India Q2 Results Live: Profit Rises by 19.77% YoY
PTC India Q2 Results Live : PTC India has declared its Q2 results on November 12, 2024, showcasing a mixed performance in ...
cnbctv182d
PTC India Q2 Results | Net profit rises 13% to ₹146 crore, revenue at ₹5,128 crore
In the corresponding quarter of the previous fiscal, PTC India posted a net profit of ₹130 crore, the company said in a ...
Multibagger Stock: PTC Industries surges over 275% in 2 years, achieves 3,200% growth in 4 years
PTC Industries stock surged 278% in two years, boosted by strong financials and significant orders, including one from Israel ...